Quigley Receives Patent Approval for Arthritis Treatment.DOYLESTOWN, Pa. -- The Quigley Corporation (Nasdaq: QGLY) announced today that the U.S. Patent and Trademark Office has approved the issuance of a patent for the company's QR-440, filed on April 23, 2003, for a naturally derived compound developed for the treatment of arthritis and related inflammatory disorders. This naturally derived compound is not a selective cyclo-oxygenase 2 inhibitor. The company believes this potential new drug will inhibit a range of inflammatory cytokines Cytokines Chemicals made by the cells that act on other cells to stimulate or inhibit their function. Cytokines that stimulate growth are called "growth factors. and in view of this non-selective mechanism of action and its natural sources, there will be a minimum of safety concerns. The company is preparing to begin pre-clinical testing, leading to a submission of an Investigational New Drug application to the U. S Food and Drug Administration, for potential approval as a prescription drug prescription drug Prescription medication Pharmacology An FDA-approved drug which must, by federal law or regulation, be dispensed only pursuant to a prescription–eg, finished dose form and active ingredients subject to the provisos of the Federal Food, Drug, . According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. the Arthritis Foundation This article or section needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. : in 2002 there were 70 million people, or one-in-three adults, suffering from arthritis in the United States; arthritis is one of the most prevalent chronic health problems and the nation's leading cause of disability among Americans over age 15; arthritis results in 39 million physician visits and more than a half million hospitalizations each year; costs to the U.S. economy totals more than $86.2 billion annually; arthritis refers to more than 100 different diseases that affect areas in or around joints. The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a leading developer and marketer of diversified health products including the COLD-EEZE(R) family of patented zinc gluconate glycine glycine (glī`sēn), organic compound, one of the 20 amino acids commonly found in animal proteins. Glycine is the only one of these amino acids that is not optically active, i.e. (ZIGG(TM)) lozenges and sugar free tablets. COLD-EEZE is the only (ZIGG) lozenge lozenge /loz·enge/ (loz´enj) [Fr.] 1. troche; a discoid-shaped, solid, medicinal preparation for solution in the mouth, consisting of an active ingredient incorporated in a suitably flavored base. 2. proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). ) products, the Company has formed Quigley Pharma Inc. (http://www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of naturally-derived patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency regulatory agency Independent government commission charged by the legislature with setting and enforcing standards for specific industries in the private sector. The concept was invented by the U.S. will grant an IND or take any other action to allow the aforementioned products to be studied or marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration. Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion